Winship Cancer Institute of Emory University
Welcome,         Profile    Billing    Logout  
 323 Trials 
1291 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olson, Jeffrey J
NRG-BN011, NCT05095376: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting
3
306
Canada, US
Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Photon Beam Radiation Therapy, Photon EBRT, Photon External Beam Radiotherapy, Radiation, Photon Beam, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
NRG Oncology, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
08/26
08/31
NCT04145115: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Suspended
2
37
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
05/25
05/25
NCT05798507: Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Recruiting
1
12
US
Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Defactinib
Emory University, National Cancer Institute (NCI), Verastem, Inc.
Glioblastoma, Recurrent Glioblastoma
10/25
10/26
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
05/25
05/27
NCT05513859: Investigational Imaging Technique During Brain Surgery

Not yet recruiting
N/A
24
US
Craniotomy, Open Craniotomy, Quantitative Oblique Back-Illumination Microscopy, qOBM
Emory University, National Cancer Institute (NCI)
Astrocytoma, Glioblastoma, Oligodendroglioma
06/26
06/27
Kucuk, Omer
EU2010-11, NCT01489813: Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Active, not recruiting
2
36
US
Genistein, Bonistein, I-Cool®, Sugar pill, Placebo pills
Emory University, DSM Nutritional Products, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Bladder Cancer
08/23
08/24
NCT04207255: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Completed
2
69
US
Opaganib, Abiraterone, Enzalutamide
Medical University of South Carolina, National Cancer Institute (NCI)
Prostate Cancer
08/23
07/24
NCT03220945: Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer

Completed
N/A
45
US
Yoga, Yoga Therapy
Emory University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Prostate Carcinoma
04/23
04/23
Dhodapkar, Madhav
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active, not recruiting
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
12/23
12/24
NCT03820817: Rifaximin in Patients With Monoclonal Gammopathy

Recruiting
1
48
US
Rifaximin, Xifaxan
Emory University, The Leukemia and Lymphoma Society
IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg
11/25
11/25
Shin, Dong M
NCT03840291: Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Completed
4
36
RoW
Edoxaban, Lixiana®
Keimyung University Dongsan Medical Center, Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Atrial Fibrillation, Left Atrial Appendage Thrombosis
10/23
08/24
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
NCT03200340: EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Completed
2
105
US
EC-18, EC-18 soft capsules, Placebo, Placebo capsule
Enzychem Lifesciences Corporation
Stomatitis
05/21
05/21
EA3163, NCT03493425: Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Recruiting
2
82
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
03/29
03/29
SB-SCI-001, NCT04812431: Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI

Recruiting
1/2
5
RoW
Neural precursor cells derived from human embryonic stem cell line
S.Biomedics Co., Ltd., Linical Co., Ltd., Yonsei University
Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion
10/28
09/30
BEAT, NCT03590730: Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy

Terminated
N/A
12
RoW
ICD implantation
Keimyung University Dongsan Medical Center, Medtronic
Valvular Heart Disease, Implantable Cardioverter Defibrillator, Sudden Cardiac Death, Primary Prevention
07/19
07/21
NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting
N/A
640
RoW
Atrial sensing On mode
Samsung Medical Center, Biotronik SE & Co. KG
Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia
12/21
05/23
NCT05078918: Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors

Recruiting
N/A
800
RoW
Comprehensive care program, Education and re-evaluation process, Usual care, Providing usual care
Samsung Medical Center, Ministry of Science and ICT, Korea
Lung Cancer, Lung Neoplasm
09/24
02/25
Waller, Edmund
NCT05616546: Bone Marrow and Peripheral Blood Immune Responses Study

Recruiting
4
90
US
Influenza Vaccine
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
12/29
12/29
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
EXPAND, NCT05714345: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Active, not recruiting
2
70
Europe, US
ALLO-647, Fludarabine, Cyclophosphamide, ALLO-501A
Allogene Therapeutics
Relapsed/Refractory Large B Cell Lymphoma
02/24
10/29
NCT03059485: DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Completed
2
82
US
DC/AML Fusion Vaccine, Observation
Beth Israel Deaconess Medical Center, Celgene, Dana-Farber Cancer Institute
Acute Myelogenous Leukemia
12/23
09/24
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NCT04890236: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recruiting
1
20
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
Emory University, National Cancer Institute (NCI), Secura Bio, Inc., Novartis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
08/24
08/25
NCT02258490: Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

No Longer Available
N/A
US
G-CSF mobilized CD34+ selected cells for transplantation
Emory University
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
 
 
NCT02843347: STRIDE Biorepository

Recruiting
N/A
200
US
Blood draw
Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
07/23
07/23
Ramalingam, Suresh
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed
1/2
24
US
ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro
Advaxis, Inc.
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
02/22
02/22
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
NCT05493566: Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/25
01/26
Blum, William
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
2
64
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
02/25
02/25
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
NCT05303792: Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults with B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Recruiting
2
66
US
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
05/26
05/28
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Recruiting
1
75
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
09/24
06/25
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
NCT04872478: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Recruiting
1
50
US
MRX-2843
Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
07/24
12/24
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
Cohen, Jonathan
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Completed
3
1453
US
Placebo, Montelukast
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
07/23
01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
3
10956
US
Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
04/24
04/24
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Completed
3
3214
US
Placebo, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
06/24
11/24
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NECTAR, NCT04924660: Novel Experimental COVID-19 Therapies Affecting Host Response

Completed
2/3
871
US
TXA127, TRV027, Placebo, Fostamatinib
Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
10/23
12/23
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05212818 / 2021-000748-24: Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

Terminated
2
19
US, RoW
TF0023, IP, Active drug
Techfields Inc
COVID-19 Pneumonia
02/23
03/23
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Completed
2
81
Europe, Canada, US, RoW
Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo
CSL Behring
Idiopathic Pulmonary Fibrosis
01/24
01/24
IPF COMFORT, NCT05185089 / 2021-006278-22: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Completed
2
80
Europe, US
Orvepitant Maleate, Placebo
Nerre Therapeutics Ltd., Pharm-Olam International
Cough, Idiopathic Pulmonary Fibrosis
06/24
06/24
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Active, not recruiting
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
07/25
07/25
NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Recruiting
1/2
285
Europe, US, RoW
SAR445877, Cetuximab, Erbitux
Sanofi, Sanofi Aventis Recherche & Développement
Solid Tumor
01/27
09/28
NCT03786926: Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Active, not recruiting
1
53
Europe, US
HMPL-689
Hutchmed
Lymphoma
07/24
12/24
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
BND-35-001, NCT06274437: A Study of BND-35 in Participants With Advanced Solid Tumors

Recruiting
1
280
RoW
BND-35, Monoclonal antibody, Nivolumab, Opdivo, Cetuximab, Erbitux
Biond Biologics
Cancer
09/27
11/27
KEYNOTE-E92, NCT05378425: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Recruiting
1
90
US, RoW
NTX-1088, Pembrolizumab, KEYTRUDA®
Nectin Therapeutics Ltd, Merck Sharp & Dohme LLC
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
06/25
12/25
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
O'Regan, Ruth
NCT04886531: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Recruiting
2
48
US
Neratinib, Nerlynx, Letrozole (L) or Anastrozole (A), Femara, Arimidex, Trastuzumab, Herceptin
Ruth O'Regan, Puma Biotechnology, Inc., University of Rochester
Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
09/25
10/25
NCT03090165: Ribociclib and Bicalutamide in AR+ TNBC

Recruiting
1/2
37
US
ribociclib, LEE011, Bicalutamide
Kari Wisinski, Novartis, Big Ten Cancer Research Consortium, University of Wisconsin, Madison
Triple Negative Breast Cancer
09/25
09/25
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
NCT03303846: Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

Active, not recruiting
N/A
344
US
Magnetic Resonance Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MRI, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Biospecimen Collection, Laboratory Biomarker Analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Healthy Subject
04/26
04/26
Li, Yan
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

Completed
4
605
RoW
Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hypertension
04/24
04/24
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication

Recruiting
4
300
RoW
Alisartan, Amlodipine besylate
Yan Li
Hypertension, Blood Pressure, Drug Use
06/26
09/26
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule

Recruiting
4
480
RoW
Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Functional Dyspepsia, Postprandial Distress Syndrome
12/23
12/23
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Active, not recruiting
3
3208
RoW
IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE
Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University
Kawasaki Disease
12/24
12/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active, not recruiting
3
488
RoW
TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis
TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
09/24
02/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa

Recruiting
3
1680
RoW
Tranexamic acid, 0.9% sodium chloride
Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital
Hemorrhage, Postpartum, Placenta Previa
02/25
04/25
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting
3
218
RoW
ICP-022, Chlorambucil, Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
06/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Not yet recruiting
2b
2250
RoW
TNM001, placebo
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
05/26
08/26
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Not yet recruiting
2
32
NA
Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT
West China Hospital
Head and Neck Neoplasms
05/23
05/25
NCT05299697: A Study of TG103 Injection in Overweight or Obesity

Recruiting
2
195
RoW
TG103 15 mg, TG103 22.5 mg, Placebo
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight or Obesity
06/23
09/23
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Recruiting
2
60
RoW
Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo
Vigonvita Life Sciences
Respiratory Syncytial Virus Infection
01/25
01/25
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting
2
60
RoW
PM8002, FOLFIRI
Biotheus Inc.
Neuroendocrine Neoplasm
01/27
01/28
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Recruiting
1/2
39
RoW
400mg of TQB3909 tablets, 600mg of TQB3909 tablets
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Mantle Cell Lymphoma
12/24
12/24
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia

Recruiting
1/2
90
RoW
BN104
BioNova Pharmaceuticals (Shanghai) LTD.
ALL, Adult, AML, Adult
06/26
06/27
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)

Recruiting
1
20
Europe
Oxaliplatin, Intraperitoneal catheter
Oslo University Hospital
Peritoneal Metastases, Colo-rectal Cancer
03/23
06/23
NCT05480592: A Study of HS-10380 in Chinese Participants

Recruiting
1
76
RoW
HS-10380, Placebo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
06/23
07/23
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose

Active, not recruiting
N/A
80
US
Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS
University of California, San Francisco
Glioma
07/27
07/27
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules

Recruiting
N/A
500
RoW
thermal ablation, thyroidectomy
Ming-an Yu
Thyroid Nodule
06/27
12/27
 

Download Options